LONDON (dpa-AFX Broker) - The British investment bank HSBC has downgraded Carl Zeiss Med itec from "Buy" to "Hold", but raised its target price from 115 to 120 euros. In a study published on Tuesday, analyst Sezgi Oezener justified the removal of the buy recommendation for the ophthalmology specialist with a limited recovery potential in China. In addition, the timing of this recovery is uncertain. In comparison, competitor Alcon offers more upside potential. In addition, the recent acquisition of the Dutch eye surgery specialist Dorc is likely to weaken Meditec's earnings profile. The expert justified the higher price target for the share with revised forecasts, among other things./tav/tih

Publication of the original study: 11.03.2024 / 21:10 / GMT

First dissemination of the original study: 12.03.2024 / 02:16 / Time zone not specified in study

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------